Efficacy and Safety of Tegoprazan‐Based Dual, Triple, and Quadruple Therapies in First‐Line Helicobacter pylori Eradication: A Prospective Randomized Controlled Trial
Helicobacter · 2026-05 · 31 (3)
DOI: 10.1111/hel.70147 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Helicobacter, online erschienen am 11.06.2026. Verfasst von Yu-Cheng Zhu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China. Hauptthemen laut MEDLINE: Helicobacter Infections, Anti-Bacterial Agents, Helicobacter pylori. Die Arbeit nennt 36 Literaturangaben. Gefördert von: Xiamen Public Hospital Reform and High-quality Development Demonstration Project, Xiamen Key Medical and Health Project.
Abstract (Originalsprache)
Background
Resistance to antibiotics has resulted in the effectiveness of conventional eradication therapies for Helicobacter pylori being reduced, creating a need for regimens that are effective, safe, and simple. In this study, we evaluated the eradication efficacy, adverse events, and medication adherence of four different tegoprazan‐based regimens administered as first‐line therapy for H. pylori infection. We also explored the clinical value of adding bismuth to a triple therapy regimen.
Methods
In this prospective, randomized controlled trial, 640 treatment‐naive patients with confirmed H. pylori infection were randomly assigned to one of the four groups undergoing 14‐day treatment regimens of tegoprazan–amoxicillin (TA), tegoprazan–tetracycline (TT), tegoprazan–amoxicillin–tetracycline (TAT), or tegoprazan–amoxicillin–tetracycline–bismuth (TATB), with 160 patients in each group. The outcomes were the eradication rate, incidence of adverse events, and medication adherence.
Results
In the intention‐to‐treat analysis, the H. pylori eradication rates in the TA, TT, TAT, and TATB groups were 80.0% (95% confidence interval [CI]: 73.0–85.9), 61.9% (95% CI: 53.9–69.4), 93.1% (95% CI: 88.0–96.5), and 89.4% (95% CI: 83.5–93.7), respectively. Compared with the TATB regimen, the TAT regimen was non‐inferior (95% CI, −3.9% to 11.5%; non‐inferiority p < 0.001), whereas demonstrating non‐inferiority in the TA and TT regimens failed. Adverse events were less frequent in the TA (10.6%), TT (17.5%), and TAT (20.0%) groups than in the TATB group (36.9%; all p < 0.001). Medication adherence was high across groups, with no significant between‐group differences observed.
Conclusions
High eradication efficacy was demonstrated for the TAT regimen; this regimen was non‐inferior to the TATB regimen, and it was associated with fewer adverse events. These findings suggest that it may be an effective first‐line treatment option for H. pylori infection. Trial Registration ClinicalTrials.gov identifier: NCT06977841
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China.
- State Key Laboratory of Cellular Stress Biology, Cancer Research Center, School of Medicine, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen, China.
- State Key Laboratory of Vaccines for Infectious Diseases, School of Public Health, Xiamen University, Xiamen, China.
- Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Wei Jiang
Förderung
- Xiamen Public Hospital Reform and High-quality Development Demonstration Project
- Xiamen Key Medical and Health Project
Zitieren
APA
Zhu, Y. C., Li, K., Sun, A., Lin, S., Zhang, J., Meng, S., Xia, X., Gao, H., Lin, J., & Jiang, W. (2026). Efficacy and Safety of Tegoprazan‐Based Dual, Triple, and Quadruple Therapies in First‐Line Helicobacter pylori Eradication: A Prospective Randomized Controlled Trial. Helicobacter, 31(3). https://doi.org/10.1111/hel.70147
Vancouver
Zhu YC, Li K, Sun A, Lin S, Zhang J, Meng S, et al. Efficacy and Safety of Tegoprazan‐Based Dual, Triple, and Quadruple Therapies in First‐Line Helicobacter pylori Eradication: A Prospective Randomized Controlled Trial. Helicobacter. 2026;31(3). doi:10.1111/hel.70147
BibTeX
@article{Zhu2026,
author = {Zhu, Yu-Cheng and Li, Keng and Sun, Anjiang and Lin, Sihui and Zhang, Jun and Meng, Shanshan and Xia, Xin and Gao, Hong and Lin, Juan and Jiang, Wei},
title = {Efficacy and Safety of Tegoprazan‐Based Dual, Triple, and Quadruple Therapies in First‐Line Helicobacter pylori Eradication: A Prospective Randomized Controlled Trial},
journal = {Helicobacter},
year = {2026},
volume = {31},
number = {3},
doi = {10.1111/hel.70147}
}
EUVIMED